A Novel Antibody-Drug Conjugate (ADC) Delivering a DNA Mono-Alkylating Payload to Chondroitin Sulfate Proteoglycan (CSPG4)-Expressing Melanoma.

Cancers (Basel) · 2020 · PMC7226475 · PMID 32331483

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

may be significantno p-value reported

These findings may be significant, since resistance can develop against the antibody or the payload components of the ADC by antigen down-regulation or mutation, or by upregulation of drug efflux transporters, respectively.

also in 11,015 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.